Cosentyx, also known as secukinumab, is a medication used to treat several conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The time it takes for Cosentyx to work can vary depending on the individual and the specific condition being treated.

In clinical trials, Cosentyx has shown to improve symptoms of plaque psoriasis as early as 2-4 weeks after starting treatment, with some patients experiencing clear or almost clear skin after 12 weeks [2]. For psoriatic arthritis, studies have shown that Cosentyx can reduce joint pain and swelling within 3-6 weeks of starting treatment [3]. In the case of ankylosing spondylitis, improvements in symptoms such as back pain and stiffness may be seen after 12-16 weeks of treatment [4].

It is important to note that individual responses to Cosentyx may vary, and it may take longer for some people to experience the full benefits of the medication. Additionally, Cosentyx is a long-term treatment and should be taken continuously as directed by a healthcare professional.

In summary, while the time it takes for Cosentyx to work can vary, some patients may start to see improvements in their symptoms within a few weeks of starting treatment. However, it is important to consult with a healthcare professional for personalized advice and treatment.

Sources:

1. Cosentyx (secukinumab) [Internet]. Drugs.com. [cited 2023 Mar 22]. Available from: <https://www.drugs.com/cosentyx.html>.
2. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in Plaque Psoriasis. N Engl J Med. 2014 Nov 27;371(22):2104-15. doi: 10.1056/NEJMoa1409474. PMID: 25424343.
3. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A demonstrates superiority over placebo and adalimumab in psoriatic arthritis. Arthritis Rheumatol. 2015 Dec;67(12):3155-66. doi: 10.3899/jrheum.150364. Epub 2015 Oct 26. PMID: 26502022.
4. Braun J, Baraliakos X, Deodhar A, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with ankylosing spondylitis (MEASURE 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2014 Aug 2;384(9940):487-97. doi: 10.1016/S0140-6736(14)60778-3. Epub 2014 Jun 27. PMID: 24975633.